Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, in subjects with renal impairment
Year: 2013
Type: article
Study design: Clinical Trial
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.12182
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1994679938
